Stockwinners Market Radar for March 23, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:08 EDT Incyte provides regulatory update on Ruxolitinib extended relief - Incyte "announced that the FDA has issued a complete response letter for ruxolitinib extended-release tablets, a JAK1/JAK2 inhibitor, for once-daily use in the treatment of certain types of myelofibrosis, polycythemia vera and graft-versus-host disease. The complete response letter states that the FDA cannot approve the application in its present form. The FDA acknowledged that the study submitted in the New Drug Application met its objective of bioequivalence based on area under the curve parameters but identified additional requirements for approval. Incyte intends to meet with the FDA to determine appropriate next steps. The NDA was based on two studies designed to show that ruxolitinib XR tablets are dosage strength proportional and bioequivalent to Jakafi(R) (ruxolitinib) tablets. The first study was designed to determine the relative bioavailability of ruxolitinib XR tablets to Jakafi tablets and to demonstrate that ruxolitinib XR tablets are dosage strength proportional to Jakafi tablets. The second study was an open-label, randomized, two-period, two-way crossover study in 63 healthy adults evaluating the bioequivalence of the highest strength of ruxolitinib XR tablets (50 mg) dosed once-daily (QD) to the highest strength of Jakafi tablets (25 mg) dosed twice-daily (BID), following a single dose and at steady-state. Study results demonstrated that ruxolitinib XR 50 mg tablets dosed QD is bioequivalent to Jakafi 25 mg tablets dosed BID, based on AUC parameters."

20:13 EDT Cathie Wood's ARK Investment sold 140K shares of Tesla today

20:12 EDT Cathie Wood's ARK Investment bought 269K shares of Coinbase today

19:29 EDT VeriSign CEO sells $2.4M in common stock - In a regulatory filing, VeriSign disclosed that its CEO James Bidzos sold 12K shares of common stock on March 21st in a total transaction size of $2.4M.

18:38 EDT Enstar Group repurchases non-voting shares of CPP Investments for $341M - Enstar Group has agreed to repurchase 1,597,712 non-voting convertible ordinary shares of Enstar held by Canada Pension Plan Investment Board - CPP Investments - for a price of $213.13 per share, totaling $341M in aggregate, representing a 5% discount to the trailing 10-day volume weighted average price of Enstar's voting ordinary shares as of the close of business on March 22 and a 13% discount to Enstar's book value per ordinary share as of the end of 2022. The shares comprise all of Enstar's outstanding non-voting ordinary shares. The transaction is scheduled to close on March 28. Following the transaction, CPP Investments will hold 9.4% of Enstar's outstanding voting ordinary shares and CPP Investments' director representative will remain on the Enstar Board. CPPIB Epsilon Ontario Limited Partnership will continue to hold 4.6% of Enstar's outstanding voting ordinary shares.

18:12 EDT Signet Jewelers CEO sells $749.5K in common stock - In a regulatory filing, Signet Jewelers disclosed that its CEO Virginia Drosos sold 10K shares of common stock on March 21st in a total transaction size of $749.5K.

17:53 EDT Gain sees dossier submission for Phase 1 clinical trial of GT-0228 by mid 2023 - Gain Therapeutics sees dossier submission for Phase 1 clinical trial of GT-02287 in GBA1 PD program by mid-2023.

17:26 EDT Motorola Solutions awarded $340.25M Air Force contract - Motorola Solutions was awarded a $340.25M firm-fixed-price, indefinite-delivery/indefinite-quantity contract for Enterprise Land Mobile Radio support. This contract provides for lifecycle management and sustainment maintenance services for the Air Force land mobile radio network. Work is expected to be complete by March 23, 2033. This award is the result of a sole source acquisition. FY23 operations and maintenance funds in the amount of $11.35M are being obligated at the time of award. The 771st Enterprise Sourcing Squadron is the contracting activity.

17:24 EDT Moving iMage board renews $1M buyback authorization - Moving iMage "announced that its Board of Directors renewed its prior authorization of a share repurchase program permitting the Company to purchase up to an aggregate of $1 million of common stock over the next 12 months."

17:07 EDT FiscalNote spikes 75% after announcing selected for OpenAI partnership - Shares of FiscalNote Holdings jumped 75% or $1.02 per share to close trading Thursday at $2.38 after being selected as one of 14 inaugural "trusted partners," and "the sole provider of legal, political, and regulatory data and information," to collaborate with AI research and deployment company OpenAI by enabling access to select FiscalNote real-time data sets and content for users of OpenAI's ChatGPT platform. "The collaboration is testament to FiscalNote's decade of aggregating and training models in the legal and political domain. FiscalNote Chairman, CEO, and Co-founder Tim Hwang added: "We're excited to collaborate with OpenAI and, as the market leader in legal and regulatory intelligence, we intend to continue to always be at the forefront as technological capabilities continue to advance. We believe this is the beginning of an innovative collaboration with a fellow AI pioneer, and we intend to continue to push the bounds of what is possible as we use this cutting-edge technology to deliver results for our global customers and advance their business objectives." The company is up another 5% in after-hours trading , to $2.50 per share on Thursday.

17:02 EDT Vasta Platform announces CEO transition plan - Vasta Platform announced a transition plan for its CEO. CEO Mario Ghio has chosen to step down from his executive role with the company. After Ghio's departure on April 30, Guilherme Melega, current COO, will assume the CEO role. Beginning in April, Ghio will assist Melega in the transition of the CEO role until April 30 and will continue to serve as a member of the Board of Directors and play a role in the company's long-term strategy. Ghio will also continue to represent the company in his role as the President of ABRASPE, the Brazilian Association of Education Systems and Platforms, an organization of companies in the sector. Melega has been with the company for almost 10 years. Between 2015 and 2017, he served as the CEO of Red Balloon, one of the company's proprietary language schools. Melega has also served in an executive capacity in other companies in the education and other sectors, such as Abril Educacao, Braskem and Whirlpool.

16:59 EDT Hyatt chief HR officer Myers sells 9,378 class A shares - In a regulatory filing, Hyatt Hotels chief HR officer Malaika Myers disclosed the sale of 9,378 class A common shares of the company on March 22 at a price of $110.59 per share.

16:54 EDT Yeti announces realignment of its commercial and sales organization - In a regulatory filing, Yeti announced on March 20, a realignment of its commercial and sales organization, which included, among other things, elimination of the position of Senior Vice President of Sales. As a result of this planned transition, on such date Yeti terminated the employment of Kirk Zambetti, who has served as Yeti's Senior Vice President of Sales since 2016. Zambetti will provide transition services as a consultant to the company for a period of three months following the termination of his employment. Following the realignment, all of Yeti's commercial functions, including those previously performed by Zambetti, will be led by S. Faiz Ahmad, Yeti's Chief Commercial Officer.

16:46 EDT Montauk Renewables announces planned entrance into South Carolina - Montauk Renewables announced its planned entrance into South Carolina with the development of a new landfill gas-to-RNG facility located in South Carolina. The planned project is expected to contribute approximately 900 MMBtu per day production capacity upon commissioning of the project. The project is expected to be completed mid-2024. The company expects to invest approximately $25M in total project costs over the next 18 months, beginning immediately.

16:40 EDT Cimpress to eliminate 500 jobs, seeks to generate about $100M in cost savings - In a regulatory 8-K filing, the company states: "On March 20, 2023, the Board of Directors of Cimpress plc approved a plan to reduce costs and implement organizational changes to support expanded profitability, reduced leverage, and increased speed, focus, and accountability. These plans include a net reduction of approximately 500 team members focused on the Vista business and Cimpress central teams. The majority of these role reductions were communicated on March 21, 2023, with the remainder expected to be completed by June 30, 2023. Certain of the planned actions are subject to mandatory consultations with employees, works councils and governmental authorities. Cimpress is also implementing significant non-compensation related cost reductions. In total, Cimpress expects these plans to generate about $100 million in annualized pre-tax cost savings. Cimpress estimates it will incur an aggregate pre-tax restructuring charge of approximately $25 million to $27 million, which includes $22 million to $24 million of severance-related expense and approximately $3 million of other restructuring charges. Of the total estimated restructuring charge, Cimpress expects approximately $23 million to $26 million of cash expenditures, which will be primarily paid in the third and fourth quarters of fiscal year 2023."

16:34 EDT Stifel Financial reports February total client assets $401,371, down 2% - Stifel Financial reported selected operating results for February 28 in an effort to provide timely information to investors on certain key performance metrics. Reports February fee-based client assets $148,015, down 2%. Reports February private client group fee-based assets $130,270, down 2%. Reports February bank loans $20,818. Reports February client money market and insured product $26,948.

16:32 EDT LivePerson divests Kasamba - LivePerson has sold Kasamba to Ingenio, a portfolio company of Alpine Investors and owner of over 30 global marketplace and media platforms focused on lifestyle, spiritual, and emotional wellness. Rob LoCascio, CEO of LivePerson, said, "LivePerson acquired Kasamba in 2007 when LivePerson was the leader in B2B chat and seeking to expand its reach to individuals who run service-based businesses such as tech support, tutoring and spirituality. We now sit at the forefront of Conversational AI for the enterprise market with a laser focus on empowering enterprises to harness and leverage proprietary data and Large Language Models. This was a great time to find a new home for Kasamba, and Ingenio is the ideal acquirer. We are grateful to the Kasamba leadership team, dedicated employees, and partners for being such a valued part of LivePerson over the years."

16:25 EDT Scholastic falls 11% to $36.90 after lowering FY23 guidance

16:21 EDT SAIC to sell logistics and supply chain management arm to ASRC Federal - ASRC Federal announced it has entered into a definitive agreement to acquire the logistics and supply chain management business of Science Applications International Corporation. With this acquisition, ASRC Federal will become a leading provider of secure, technology-enabled supply chain management and logistics solutions for the Defense Logistics Agency which provides services to Department of Defense agencies, including the U.S. Army, U.S. Air Force and U.S. Navy on a global scale. The to-be-acquired business is a natural fit with ASRC Federal's base operations support capability that currently provides procurement, logistics and warehousing services at military locations throughout the United States. Upon close, ASRC Federal will add about 240 professionals. The transaction is expected to close in Spring 2023 and is subject to customary closing conditions.

16:20 EDT Hawaiian Holdings and Gevo sign sustainable aviation fuel sales agreement - Hawaiian Airlines has reached an agreement with biofuel company Gevo to purchase 50 million gallons of sustainable aviation fuel - SAF - over five years. Gevo expects to supply the SAF from a facility to be constructed in the Midwestern United States and begin deliveries to Hawaiian's gateway cities in California starting in 2029. Gevo will produce SAF using residual starch from inedible field corn, grown using regenerative farming practices. The production process also will utilize renewable electricity and renewable natural gas, resulting in low-carbon fuels with substantially reduced carbon intensity. The fuel sales agreement is subject to certain conditions precedent, including Gevo developing, financing, and constructing the facility to produce the SAF contemplated by the agreement.

16:18 EDT Nelnet reducing staff due to lower pricing and reduced DoE loan servicing - Nelnet announced a staffing reduction to address lower pricing and reduced servicing volume for the company's federal servicing contracts as well as to align with the company's strategic consolidation and sunsetting of select loan servicing systems. On March 22, Nelnet received a contract modification from the Department of Education for the company's current loan servicing contracts with the Department, which decreased the price earned by the company per borrower per month. Additionally, last month, the Department notified Nelnet of its intent to transfer 1 million borrowers from Nelnet Loan Servicing to another federal servicer over the next few months. The transfer was not based on Nelnet's performance. Both the price reduction and the unanticipated transfer of a million borrowers will have a material impact on NDS. Approximately 550 associates who work in Nelnet's Diversified Services division and some in related shared services areas that support NDS were notified today their positions are being eliminated. Nelnet will also look for redundancies and efficiencies throughout the year related to the conclusion of projects centered on the consolidation of select loan servicing platforms. No other Nelnet businesses are impacted. Throughout the remainder of the year, the company will strategically continue migrating borrowers from legacy systems to platforms and then sunset the legacy systems, with the goal of creating ongoing efficiencies.

16:15 EDT Albany International CFO Stephen Nolan resigns - Albany International "announced it has accepted the resignation of its Chief Financial Officer and Treasurer, Stephen Nolan, effective April 7, 2023. The Company further announced that its Board of Directors has appointed Robert D. Starr as Chief Financial Officer and Treasurer to succeed Mr. Nolan, effective April 10, 2023. Mr. Nolan has informed the Company that he has accepted an opportunity at a private company."

16:10 EDT MiMedx announces CFO Peter Carlson leaving, company initiates search - MiMedx Group announced that Peter Carlson, Chief Financial Officer, has decided to leave the Company to pursue other opportunities. The Company has initiated a search for its next Chief Financial Officer and Mr. Carlson will be assisting MIMEDX throughout this process to ensure a smooth transition."In the three years Pete has been with MIMEDX, he has played a critical role bringing excellence to our finance and accounting functions," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "As a result of his leadership, we are on sound footing. More specifically, Pete helped the Company raise debt and equity to strengthen the Company's financial position, successfully led MIMEDX out of a de-listing, enhanced our internal controls and was the architect of our new segment reporting. We are extremely appreciative of Pete's contributions and accomplishments and wish him our sincere best in his future endeavors."

16:06 EDT dMY Technology Group, Inc. VI to transfer to Nasdaq after Rainwater Tech deal - dMY Technology Group, Inc. VI announced its intention to transfer its stock exchange listing from the New York Stock Exchange to the Nasdaq Stock Market, effective upon the completion of its previously announced business combination with Rain Enhancement Technologies, a leader in the development of rainfall generation technology. Upon the consummation of the business combination, Rainwater Tech will be a wholly owned subsidiary of dMY VI, and dMY VI will change its name to "Rain Enhancement Technologies, Inc." Once the business combination is completed and once authorization for listing on Nasdaq has been received, dMY VI will change its trading ticker from DMYS to the new ticker symbol "RANY" and will begin trading on Nasdaq.

16:03 EDT Scholastic board authorizes additional $50M for share repurchases - The company's Board of Directors has authorized an additional $50M for repurchases of its common stock under the company's stock repurchase program. This authorization increases the aggregate amount of shares, in dollar terms, which may now be repurchased to over $75M.

15:46 EDT Air Products confirms withdrawal from Indonesia coal gasification projects - In response to media reports, Air Products confirmed that it is no longer involved in the coal-to-methanol Bengalon, East Kalimantan, Indonesia project, nor in other coal gasification projects in Indonesia. The financial landscape for blue and green hydrogen projects has significantly changed in the last year, driving increasing opportunities for Air Products to invest in these energy transition projects around the world. As a result, the company has decided to redeploy its financial resources on such energy transition opportunities. Air Products remains committed to its core industrial gas business in Indonesia.

15:32 EDT Norfolk Southern, SMART-TD shifting focus in negotiations - Norfolk Southern and the International Association of Sheet Metal, Air, Rail and Transportation Workers - Transportation Division, or "SMART-TD," announced that they are discontinuing formal negotiations regarding conductor redeployment to "focus their efforts on implementing other immediate quality-of-life improvements for their employees." Under the terms of the national agreements, Norfolk Southern and SMART-TD have a mid-June deadline to negotiate the details of these scheduling enhancements. Given this limited window, Norfolk Southern has withdrawn its current Section 6 bargaining notice on conductor redeployment to fully focus on collaboratively implementing these enhancements and other quality-of-life priorities. Jeremy Ferguson, president of SMART-TD, said: "These scheduling enhancements, which were part of last year's national agreements, have the potential to make an immediate positive impact for our conductors by giving them fixed days off and greater certainty about their weekly assignments. The willingness of NS to step back from plans to change to a ground-based conductor model is a welcome show of good faith in the negotiation process."

13:34 EDT Block exploring legal action against Hindenburg after 'misleading' report - Block said in a statement: "We intend to work with the SEC and explore legal action against Hindenburg Research for the factually inaccurate and misleading report they shared about our Cash App business today. Hindenburg is known for these types of attacks, which are designed solely to allow short sellers to profit from a declined stock price. We have reviewed the full report in the context of our own data and believe it's designed to deceive and confuse investors. We are a highly regulated public company with regular disclosures, and are confident in our products, reporting, compliance programs, and controls. We will not be distracted by typical short seller tactics."

13:17 EDT Freight Technologies announces 10-for-1 reverse share split - Freight Technologies announces a reverse share split intended to increase the market price per share of the company's ordinary share and allow Freight Technologies Inc. to bring the company into compliance with Nasdaq's minimum bid price requirement and maintain its Nasdaq Capital Market listing. The company confirms that, as previously announced, the board of directors on March 3, 2023, approved a 10:1 reverse split of its ordinary shares, effective on or around March 24, 2023. Freight Technologies Inc.'s ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "FRGT," but will trade under a new CUSIP number.

12:52 EDT Portfolio Recovery Associates announces settlement of CFPB matter - PRA Group announced that its subsidiary, Portfolio Recovery Associates, has reached an agreement with the U.S. Consumer Financial Protection Bureau. As part of the settlement, PRA has agreed to pay a penalty of $12M and approximately $15M to impacted consumers, who represent less than one-tenth of 1% of PRA's active accounts. The majority of the financial impact of the settlement was reflected in our December 31, 2022, financial statements. This agreement is not expected to have a material adverse impact on the company's financial condition or results of operations. PRA Group, Inc. President and CEO Kevin Stevenson said, "Our company was founded on the principles of treating customers with fairness and respect, and we have prided ourselves in upholding these values for more than 27 years. Although we have admitted to no wrongdoing as part of the resolution, and we continue to disagree with the CFPB's characterization of our conduct, we are pleased to have this matter resolved and behind us, allowing us to return our full attention to our impactful work with consumers, promoting their journey toward financial recovery."

12:30 EDT Robert Half names Susan Haseley chief ESG and DEI officer - Robert Half has promoted Susan Haseley to chief environmental, social, governance and diversity, equity and inclusion officer, leading enterprise strategy and programming for Robert Half, including its consulting subsidiary, Protiviti. "As our commitment to ESG and DEI continues to deepen, this enterprise-wide leadership position is designed to align and strengthen our efforts globally," said M. Keith Waddell, president and chief executive officer of Robert Half. "Under Susan's leadership, we will continue to focus on initiatives that help us sustain a people-first approach in our workplace and enhance our support of the communities where we live and work."

12:00 EDT Block falls -13.2% - Block is down -13.2%, or -$9.58 to $63.07.

12:00 EDT On Holding rises 12.9% - On Holding is up 12.9%, or $3.53 to $30.89.

12:00 EDT Worthington rises 17.1% - Worthington is up 17.1%, or $9.07 to $62.20.

11:27 EDT Booking Holdings becomes official online travel partner of MLB - Booking.com has signed on as the Official Online Travel Partner of Major League Baseball in the United States. The company said, "With Booking.com's mission to make it easier for everyone to experience the world, the goal of this strategic partnership with MLB is to simplify the way Americans plan their unique baseball-inspired travels across the U.S. As part of this long-term partnership, Booking.com is now the presenting sponsor of the American and National League Division Series, too."

11:21 EDT Five9 expands partnership with Invoca for PreSense solution - Five9 and Invoca announced they have expanded their strategic partnership to deliver a solution that enables deeper insight into real-time data throughout the entire customer journey and brings the contact center and the marketing teams closer together to enable more "fluid" CX. The companies said, "This customized solution called PreSense, combines the power of Five9 Intelligent CX Platform with Invoca's conversation intelligence technology, giving contact center agents visibility into a caller's digital journey before the call takes place. Insights from PreSense help reduce call handling times, increase contact center productivity, and help enable more fluid customer experiences that flow effortlessly through channels, and between virtual and human agents."

11:15 EDT Maxpro Capital Acquisition Corp trading halted, volatility trading pause

10:37 EDT Cuentas announces 1-for-13 reverse stock split - Cuentas announced that the company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 13. The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on March 24, 2023 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on March 24, 2023 under the Company's existing trading symbol "CUEN". At such time, the Company's common stock will also commence trading under a new CUSIP number 229794300. The company said, "We expect that the Reverse Stock Split will increase the market price per share of the Company's common stock, bringing the Company into compliance with listing requirements for The Nasdaq Capital Market."

10:14 EDT Kludein I Acquisition Corp trading resumes

10:02 EDT CV Sciences reports formal notice of patent issuance from JPO - CV Sciences announced that recently the company received its formal Certificate of Grant from the Japan Patent Office, or JPO, for its patent application 7216697, which covers methods of treating smokeless tobacco addiction by administering pharmaceutical formulations containing CBD and nicotine. "CV Sciences has also filed corresponding patent applications that provide similar patent protection in additional key markets, with patents already granted in the United States, Canada, Australia, Germany, Great Britain, France, Spain, Netherlands, and Italy," the company stated.

10:00 EDT Movado falls -15.7% - Movado is down -15.7%, or -$5.17 to $27.85.

10:00 EDT Select Energy Services rises 9.9% - Select Energy Services is up 9.9%, or 59c to $6.59.

10:00 EDT Steelcase rises 14.1% - Steelcase is up 14.1%, or $1.01 to $8.19.

09:47 EDT Chewy falls -5.7% - Chewy is down -5.7%, or -$2.14 to $35.62.

09:47 EDT Block falls -19.9% - Block is down -19.9%, or -$14.47 to $58.17.

09:47 EDT Select Energy Services rises 8.5% - Select Energy Services is up 8.5%, or 51c to $6.51.

09:41 EDT Knightscope reports order from south Florida university - Knightscope announced that a university in southern Florida has purchased three of its K1 Blue Light Emergency Phones through Transportation Solutions & Lighting, a Florida based reseller of Knightscope technologies. TS&L purchased 40 K1 Blue Light Towers earlier this month to support its growing emergency communications business, Knightscope said.

09:38 EDT DiamondHead Holdings Corp trading halted, volatility trading pause

09:36 EDT Fat Brands enters development deal to open 20 Johnny Rockets in Mexico - FAT Brands announces a new development deal set to bring 20 additional franchised Johnny Rockets locations to Mexico in the next 10 years. The brand currently operates approximately 25 restaurants throughout the country. The new locations will open in partnership with franchisee Virko Restaurantes S.A. de C.V.

09:29 EDT Entera Bio regains compliance with Nasdaq listing requirements - Entera Bio received notice from The NASDAQ Stock Market LLC (NASDAQ) on March 23, 2023, informing Entera that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. On November 21, 2022, NASDAQ notified the Company that its ordinary shares had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. Since then, NASDAQ determined that for the last 14 consecutive business days, from March 3rd through 22nd 2023, the closing bid price of the Company's ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and this matter is now closed. Entera is in compliance with all applicable listing standards, and its ordinary shares continues to be listed on The NASDAQ Capital Market.

09:26 EDT Alkaline Water achieves nationwide distribution in Whole Foods Market stores - Alkaline Water announced that its Alkaline88 1-Gallon product has successfully attained full nationwide distribution in all Whole Foods Market stores. The most recent expansion has placed the popular product in 306 additional locations, spanning six divisions-Mid-Atlantic, Midwest, Northeast, North Atlantic, Northern California, and Rocky Mountain.

09:14 EDT Snap unveils AR Enterprise Services - Snap unveiled AR Enterprise Services, or ARES, a new enterprise solution to enable businesses to integrate Snap's Augmented Reality, or AR, into their owned and operated channels with ease and at scale. Through this offering, consumers will enjoy immersive and personalized experiences with their favorite brands, with a suite of advanced tools designed to increase confidence in their purchases. ARES' inaugural offering is for retail, and among the first group of customers are Goodr, Princess Polly, and Gobi Cashmere. Each of these companies have been using various products from Fit Finder to AR Try-On, which are features that make up our new Shopping Suite.

09:12 EDT Verizon announces Free Trial with 30 days of 5G Ultra Wideband - The company said, "Attention non-Verizon customers on sub-par networks: The time to switch to Verizon is now! Starting today, sign up for Verizon Free Trial and get 30 days of unlimited data on Verizon's fastest 5G network totally free, with no costs, no catches and no credit card required. No, really. You can use your existing eSIM-capable smartphone and Free Trial will not affect your current plan, number or contract."

09:12 EDT DoorDash announces new retail partnerships and shopping features - "Over the past several years, we have drastically accelerated our growth beyond restaurants to meet evolving consumer needs and expectations for convenience. Since day one, our merchant-first approach has guided us to build products and services that best serve every business on Main Street, helping to bring them online, reach more customers, and compete in new ways. Now, DoorDash has more than 100,000 non-restaurant stores across our Marketplace and Drive platforms in North America. Today, we're excited to announce several new retail partners on DoorDash including Lush Cosmetics, Victoria's Secret, and Party City. Plus, new shopping features to give consumers a more seamless experience including delivery windows, express delivery, enhanced search within retail stores, and frictionless in-app communication. ..Through the significant headway we've made in our selection efforts on the platform and investments in new verticals, more than 98% of our monthly consumers in the U.S. have access to a non-restaurant retail store on DoorDash...We continue to build and invest in products and initiatives to support retail partners' overall experience and drive their success on our platform. In tandem, we're focused on helping consumers access anything they need in their local neighborhood with ease, speed, value, and convenience.

09:08 EDT T2 Biosystems affirms plan to add Candida Auris detection to T2Candida panel - T2 Biosystems affirmed plans to add detection of the fungal pathogen Candida auris to the Company's FDA-cleared and CE marked T2Candida Panel. According to a March 21, 2023 Wall Street Journal report, Candida auris is a multidrug-resistant pathogen labeled by the Centers for Disease Control and Prevention and World Health Organization as a growing threat to public health. "With prior support from the CDC, we have completed feasibility and early development of a diagnostic test to detect the Candida auris pathogen directly-from-blood and we plan to add this test to our FDA-cleared T2Candida Panel," stated John Sperzel, Chairman and CEO of T2 Biosystems. "We believe adding Candida auris detection to our existing T2Candida Panel can accelerate time to detection and targeted treatment, compared to blood culture-based diagnostic methods, and we are exploring partnerships to accelerate our path toward commercialization."

09:08 EDT Capstone Green Energy distributor Cal Microturbine gets 3 microturbines orders - Capstone Green Energy announced that Cal Microturbine, Capstone's exclusive distributor for California, Hawaii, Nevada, Oregon and Washington, secured three orders for Capstone C1000 Signature Series microturbines. Darren Jamison, President and CEO of Capstone Green Energy, explained, "The flexibility of Capstone's microturbines is showcased through a range of customer applications, including oil and gas production, brewery operations, and renewable natural gas processing. This is only the beginning of the technology's potential uses, along with other applications such as hospitality and agriculture installations, and EV charging." According to Jamison, "Customers consistently report that Capstone microturbines provide dependable power, while also helping them achieve their environmental objectives."

09:07 EDT Bayer, Orion expand clinical development program for darolutamide - Orion and Bayer further expand the global clinical development program for the oral androgen receptor inhibitor darolutamide in prostate cancer. The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline. BCR is defined as rising prostate-specific antigen levels with a doubling time of less than12 months1 after primary treatment. Darolutamide is already approved under the brand name Nubeqa for the treatment of patients with non-metastatic castration-resistant prostate cancer, who are at high risk of developing metastatic disease as well as metastatic hormone-sensitive prostate cancer. The compound is also being investigated in further studies across various stages of prostate cancer, including in the ARANOTE Phase III trial evaluating darolutamide plus androgen deprivation therapy versus ADT alone for metastatic hormone-sensitive prostate cancer, as well as the Australian and New Zealand Urogenital and Prostate Cancer Trials Group led international Phase III co-operative group DASL-HiCaP trial evaluating darolutamide as an adjuvant treatment for localised prostate cancer with very high risk of recurrence.

09:06 EDT Curtiss-Wright awarded communications modernization follow-on order from USMC - Curtiss-Wright announced that it has been awarded a follow-on contract by the United States Marine Corps USMC to provide small form factor network router and switch modules to support communications modernization with highly portable expeditionary network communications technology. Under the contract, Curtiss-Wright will provide a Modular Open Systems Approach MOSA deployed baseband system for the Marine Corps Wideband Satellite-Expeditionary program. "As a leading supplier of tactical battlefield communications solutions, we are very proud to provide the Marine Corps with our proven field-deployable network communications technology to support the MCWS-X program," said Lynn M. Bamford, Chair and CEO of Curtiss-Wright Corporation. "This contract further strengthens the long and successful relationship we have with the USMC and highlights Curtiss-Wright's ability to enhance interoperability and improve cost efficiencies with electronics systems that adhere to the DoD's mandate for solutions based on the Modular Open Systems Approach." Curtiss-Wright is performing the work within its Defense Solutions division in the Defense Electronics segment. The products covered by this agreement will be shipped to the USMC from the Curtiss-Wright Defense Solutions facility in Portland, Oregon.

09:05 EDT Lucy Scientific Discovery announces partnership with High Times - Lucy Scientific Discovery announced the launch of a new line of unscheduled psychoactive compounds that will be available for sale throughout the United States, and where permitted throughout the rest of the world. The first line in the new family of brands contains Amanita Muscaria mushrooms, a psychoactive adaptogen. This product line is named 'Mindful by Lucy'. Lucy Scientific will produce Mindful with High Times, through a strategic partnership with Hightimes Holding. With a product launch targeted for Q2 2023, this new line is well-positioned to capitalize on the growing market for psychoactive alternatives, which Forbes predicts will double to over $5 billion in gross sales by 2025. Chris McElvany, Chief Executive Officer of Lucy Scientific Discovery, stated, "As awareness and acceptance of alternative treatments for various conditions, such as PTSD, anxiety disorders, and depression, continue to grow, adaptogens are emerging as a leading therapeutic remedy. This partnership between Lucy and High Times will enable the two companies to expand the reach of Lucy's products and promote the potential health benefits to a broader audience."

09:03 EDT ContextLogic partners with ShipSage to provide faster order fulfillment - ContextLogic announced an agreement with ecommerce fulfillment service provider ShipSage to provide merchants with more options and swifter fulfillment when completing orders from Wish shoppers across the United States. Through the agreement, Wish merchants that sign up for ShipSage's fulfillment service will gain access to its warehousing facilities and ecommerce fulfillment services through its network of warehouses across the U.S.. Wish merchants utilizing ShipSage's fulfillment service will have the possibility of bringing their average Time to Door in the U.S. down to 2-3 days. "We're on a mission to transform our business, and this extends to the shipping experience we provide to our customers. In the past year, we've made a lot of improvements to our overall Time to Door and On Time delivery rates, and want to build on that success by providing even more fulfillment options to our US based merchants," said Sarah Luo, VP of Merchant Operations at Wish. "By partnering with ShipSage, our US merchants can leverage their operational excellence to deliver an overall better experience to our users."

08:55 EDT Block extends decline to 20% after Hindenburg Research short report

08:43 EDT Jaguar Health appoints Kelly Shanahan to Scientific Advisory Board - Jaguar Health announced that Dr. Kelly Shanahan, a former clinician and a metastatic breast cancer patient who is now a full-time independent patient advocate, has joined the Jaguar/Napo Scientific Advisory Board.

08:41 EDT Trupanion announces CFO Wolff to step down, Li to serve as interim CFO - Trupanion announced the following changes to its executive leadership team: Drew Wolff, Chief Financial Officer, will be stepping down from his position effective June 1, 2023. Thereafter, Wolff will serve as a senior advisor to the Company to support the Interim CFO, and to assist in the search and training of the incoming CFO. Trupanion has initiated an executive search for a new full-time CFO. Wei Li, Corporate Controller, will assume the position of Interim Chief Financial Officer upon Wolff's departure. Li joined Trupanion in 2018. Tricia Plouf, EVP of Pricing, and Gavin Friedman, EVP of Legal & Regulatory, will be departing the Company, effective immediately.

08:40 EDT Evoke Pharma, EVERSANA announce real-world data on impact of GIMOTI - Evoke Pharma and EVERSANA Life Science Service announced a summary of real-world data on the positive impact of GIMOTI usage in decreasing the utilization of healthcare resources by patients with diabetic gastroparesis. The data describes results of a study that highlights healthcare resource utilization data, HCRU, in diabetic gastroparesis patients before and after taking GIMOTI. Select data points and key findings from the real-world evidence study are outlined below: Of the 294 patients, 60.5% received oral metoclopramide prior to initiation of GIMOTI and 43.8% were treated with oral metoclopramide in the immediate six months prior to the initiation of GIMOTI; 77% of patients studied were female with an average age of 52.1 years; Patients received an average of 2.6 prescriptions for GIMOTI during the six-month follow up period; For All-Cause HCRU data, the mean number of physician office visits was significantly less in the post-period at 2.0 compared to the pre-period at 2.2; For Nausea, Vomiting and DGP-associated HCRU data, the mean number of physician office and hospital outpatient visits was significantly less in the post-period for dropping 0.29 to 0.18 and 1.6 to 1.0 respectively. Conclusions: For DGP-related HCRU both Office Visits and Hospital Outpatient Visits significantly declined in the post-period vs. pre-period, respectively. The mean number of All-Cause Office Visits was significantly less in the post-period vs. the pre-period. There were fewer inpatient hospitalizations and Emergency Department visits for both All-Cause and DGP related although statistical significance was not achieved.

08:38 EDT ZimVie announces article on its Puros Cancellous Particulate Allograft - ZimVie announced the publication of an article titled Comparison of the Effects of Tissue Processing on the Physicochemical Properties of Bone Allografts in The International Journal of Oral & Maxillofacial Implants. ZimVie Dental's Puros Cancellous Particulate Allograft bone substitute was shown to have a microstructure and preserved collagen matrix that suggests a higher ability to support bone formation than competitive freeze-dried allografts. The article looked at the impact of different tissue processing methods on the physicochemical properties of allografts, including Puros Cancellous Particulate Allograft, Creos, OraGraft, and MinerOss. The article highlights that the surface area of Puros Cancellous Particulate Allograft was 100 times higher than that of the freeze-dried allografts. A higher surface area as well as the strength and health of grafted sites are critical in implant dentistry, as an implant is only as strong as the bone that supports it. It further examined collagen fiber bundles and individual fibril arrangements on ZimVie's Puros Cancellous Particulate Allograft compared to unprocessed human bone tissue. "The collagen microstructure of Puros Cancellous Particulate Allograft - and the size of individual fibers - was almost identical," states the research article. The surface area and microscopic texture of Puros Cancellous Particulate Allograft resulted in a significantly higher response from a specific type of stromal cells in vitro.

08:37 EDT Smart for Life enters into distribution agreement with BOXOUT - Smart for Life announced a new distribution agreement, through its wholly owned subsidiary Ceautamed Worldwide, with Boxout, a national distributor of medical, rehabilitation, and health & wellness products. Under the agreement, Boxout will distribute the Company's proprietary Greens First products through its established distribution channels, which include medical, physical therapy and chiropractic offices across North America. Smart for Life and Boxout also plan to launch new e-commerce initiatives on marketplace platforms. "We are excited to expand our partnership with Boxout for distribution of our Greens First product line. Boxout is a prominent national distributor, and we believe their scalable solutions can help us cost-effectively optimize our distribution strategy," stated Darren Minton, Smart for Life's Chief Executive Officer. "Boxout has a proven track record with a number of leading brands, and we are proud to be a part of that leading roster. Moreover, we look forward to leveraging their broad national distribution network."

08:36 EDT ReShape Lifesciences announces formation of international SAB - ReShape Lifesciences announced the formation of a Scientific Advisory Board, SAB. Members include internationally recognized experts and surgeons in the obesity and metabolic disease fields. The newly created SAB will provide management with strategic input and external scientific review of the company's development activities and product pipeline. "The establishment of a SAB will provide us access to an extensive and unparalleled knowledge base as well as relationships and insights that will be invaluable as we continue to execute on our disciplined approach to drive revenue and expand our product pipeline, including our next-generation Lap-Band 2.0, which we expect to submit to the U.S. Food and Drug Administration for approval during the first half of this year," stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. Members of the ReShape SAB include: Caroline Apovian; Michael Baptista; Matt Brengman; John Dixon; Francesco Furbetta; Darrin Hansen; Michael Orris; Carl Pesta; Jaime Ponce; Christine Ren-Fielding; Adam Smith; Shaw Somers; Erik Wilson.

08:33 EDT Vimeo appoints Glenn Schiffman as non-executive chairman - Vimeo announced the appointment of Glenn Schiffman as its new non-executive Chairman. Mr. Schiffman served as the CFO of IAC, Inc. from 2016 to 2021 and has served as a member of the Company's Board of Directors since its spin-off from IAC in 2021. He will succeed Joey Levin, who is stepping down as Chairman and member of the Board of Directors due to his other executive and board commitments, including his recent appointment as CEO of Angi, Inc., his continued service as CEO of IAC, and his positions on the boards of IAC, Angi and MGM Resorts International. Mr. Levin will continue to stay actively involved in Vimeo as Special Advisor to the board and management. With these changes, the Board of Directors is now composed of ten directors, seven of whom are independent.

08:31 EDT Mobiquity Technologies unveils ATOS 2.0 platform - Mobiquity Technologies announces the launch of its ATOS 2.0, an advertising platform designed with user privacy, data protection, and the Apple AppTrackingTransparency framework in mind. This industry-first ad tech ecosystem combines the power of cutting-edge technology, machine learning, and industry expertise to deliver an unparalleled advertising experience for advertisers and end-users alike.

08:19 EDT SpringBig announces expansion of partnership with Shopify, KORONA POS - springbig (SBIG) announced an expansion of its partnerships with Shopify (SHOP) and KORONA POS, the leading cloud point-of-sale, POS, solution for small business to enterprises, from software vendor COMBASE. Both partnerships draw on springbig's vast experience working with retailers across multiple verticals and have created new, innovative embedded loyalty solutions that help brands thrive in highly competitive industries. "We are thrilled with the success of our strategic partnerships with both KORONA POS and Shopify," said Jeffrey Harris, CEO of springbig. "Both partners have been instrumental in offering solutions that help businesses connect with their customers and create strong bonds. In the future, we are excited to continue building new technological solutions that will make the consumer experience as fulfilling and seamless as it should be."

08:14 EDT Jasper Therapeutics appoints Adelman as acting CMO - Jasper Therapeutics announced the appointment of Daniel Adelman, M.D., as the company's Acting Chief Medical Officer, CMO. Dr. Adelman is a highly experienced clinical leader and innovator and brings to Jasper more than 30 years of experience in the clinical development of novel therapies for immunologic diseases. Previously Dr. Adelman served as Vice President of Clinical Operations and Biometrics at Pharmacyclics, and as a Clinical Scientist at Genentech where he was involved in the early development of omalizumab and bevacizumab.

08:13 EDT Stifel Financial announces significant expansion of venture banking business - Stifel Financial (SF) announced a significant expansion of its business serving growth companies in the venture community through the addition of three key partners formerly with Silicon Valley Bank (SIVB). Jake Moseley, Matt Trotter, and Ted Wilson all join Stifel as Managing Directors and will immediately assume leadership roles in Stifel's Venture Banking Group. They are based in the San Francisco Bay area. Messrs. Moseley, Trotter, and Wilson will join Stifel veterans Brad Ellis and Nat Stone as members of a five-person operating committee dedicated to delivering commercial banking and lending solutions to help clients succeed and scale across all business sectors. Jake Moseley as most recently, he was Head of Relationship Management Technology Banking at SVB. Prior to joining Stifel, Matt Trotter was a Senior Market Manager and Head of Frontier Technologies and Climate Technology and Sustainability at SVB. Ted Wilson joins from SVB, where he was Head of Enterprise Software.

08:11 EDT AnPac Bio granted continued, conditional listing by Nasdaq - AnPac Bio has been notified by the Nasdaq Hearings Panel of the Listing Qualifications Department of Nasdaq that the company's request for continued listing on The Capital Market has been granted, subject to the requirement that the company demonstrate on or before July 12, its compliance with the shareholder equity requirement. The Panel advised that July 12 represents the full extent of the Panel's discretion to grant continued listing while the company is non-compliant. The Panel noted that the company indicated that while it has already cured the shareholder equity deficiency, it plans to continue engaging in fund-raising activities throughout the year to maintain its shareholder equity value. The Panel also noted that the company outlined its plan to reduce expenses and acquire a cash generating business in order to improve its financial position. The Panel indicated that it believes the company has articulated a reasonable plan and should be afforded time to implement this new strategy.

08:10 EDT electroCore reports results of pre-clinical trial in model of TBI - electroCore announced the publication of a paper entitled "Non-Invasive Vagus Nerve Stimulation Improves Brain Lesion Volume and Neurobehavioral Outcomes in a Rat Model of Traumatic Brain Injury" in the peer-reviewed Journal of Neurotrauma. The lead author is Dr. Afshin Divani of the University of New Mexico, who is the primary investigator leading the study. The study design included low dose non-vagus nerve stimulation, high dose nVNS, and control arms, and stimulated 5 or 10 times over an hour, beginning 30 minutes post-TBI in a rodent model. Magnetic Resonance Imaging studies on Day 1 and 7 revealed smaller brain lesion volume among the nVNS groups compared with the control group. On Day 1, these abnormal volume changes were 13% and 55% smaller in the lower dose and higher dose nVNS groups, respectively, as compared with the control group. By Day 7, nVNS decreased the size of the cortical lesion by 35% and 89% in the low dose and high dose nVNS groups, respectively, as compared with the control group. The control group showed significant deficits in three common neurobehavioral assessments including rotarod, anxiety, and modified beam walking performances. All these deficits were significantly reduced in the high dose nVNS group on Day 1 and the two anxiety indices were also reduced on Day 7 post-injury as compared with the control group. MRI data suggest that the benefits may be caused by a decrease in the deformation and swelling of brain tissue after TBI. Additional work on the potential benefits of nVNS on TBI will be funded by an Exploratory/Development Research Grant from the National Institute of Neurological Disorders and Stroke.

08:09 EDT Bird Global announces Greater Toronto area expansion beginning this spring - Bird Global announced that it will be expanding across the Greater Toronto Area this Spring. Bird will be the exclusive operator of shared e-scooters in the City of Hamilton beginning April 3rd, 2023, and will operate shared e-scooter fleets in both Brampton and Oshawa in the coming weeks. All three launches follow rigorous RFP processes in which Bird was selected based on its commitment to safe, sustainable, and reliable transportation. These new markets build on Bird's footprint in Canada, solidifying its position as the biggest shared micromobility operator in Canada, and a leader around the world. Bird will now operate in five cities in Ontario, including Ottawa and Windsor, as well as 11 other cities across Canada. These new markets will expand on Bird's already full year-EBITDA positive operations in Canada.

08:08 EDT Nisun International signs strategic cooperation agreement with Gold of China - Nisun International's controlled affiliate, Fintech Supply Chain Shandong, has entered into a strategic cooperation agreement with Gold of China, a company engaging in the gold wholesale and jewelry retail in China. The Chinese gold market is the world's largest physical gold market. It is also one of the world's most protected gold markets given that the importation of gold into China is still strictly controlled by the Chinese authorities, and the exportation of gold out of China is generally prohibited.

08:05 EDT Nokia chosen by CANARIA as sole IP router provider - Nokia announced that CANARIE has chosen the Nokia 7750 Service Router as the IP/MPLS platform to support its more than 34,000 km network connecting 13 provincial and territorial networks to each other and to more than 100 NRENs around the world.

08:05 EDT Huntington Bancshares raises prime rate to 8.00% from 7.75%, effective March 23

08:04 EDT Alaska Air signs agreement with Shell Aviation for sustainable aviation fuel - Alaska Airlines (ALK) announced an agreement with Shell (SHEL) Aviation to expand the sustainable aviation fuel -SAF - market beyond a standard fuel supply agreement. Details of the agreement include commitments to deepen understanding of the technology, infrastructure, carbon accounting systems and public policy support needed to bring SAF to more markets, in greater quantities and at a more sustainable long-term cost. The companies will put particular focus on enabling supply to the West Coast and alleviating fueling infrastructure challenges in the Pacific Northwest. Shell Aviation will also supply up to 10 million gallons of neat SAF to Alaska Airlines at their hub in Los Angeles. SAF is a safe, certified drop-in fuel that meets the jet fuel standards to reduce carbon emissions by as much as 80% of lifecycle emissions.

08:04 EDT Wireless Telecom reports Q4 adjusted EPS 2c vs (1c) last year - Reports Q4 revenue $6.739m vs $5.897M last year. Tim Whelan, CEO of Wireless Telecom Group, Inc. stated, "We successfully executed upon our previously communicated strategic alternatives plan in 2022, closing on the sale of both our Microlab business and CommAgility business. We now have nearly $21 million of cash on our balance sheet, no debt or earn-out liabilities, and we believe we have successfully transitioned our business model to a focus on the single remaining segment, our Test & Measurement business."

07:57 EDT Evaxion Biotech develops AI platform technology ObsERV - Evaxion Biotech announces that it has developed a new proprietary AI platform technology ObsERV to identify a new source of targets for personalized cancer therapy, potentially enabling treatment of patients that are currently considered unresponsive to cancer immunotherapy. ObsERV, Evaxion's new proprietary AI platform technology, identifies patient-specific virus targets, so-called ERVs, expressed in cancer. Evaxion has demonstrated that overexpression of such ERVs is strongly associated with the overall survival of cancer patients, notably of patients that are normally considered unresponsive to immunotherapy. In addition, the Company has preclinically demonstrated complete tumor eradication in animal models when targeting ERVs.

07:51 EDT Principal Solar divesting activities, investments not in line with new focus - Principal Solar released a letter to its shareholders from K. Bryce Toussaint, CPA, MBA, the Company's Chairman and CEO, which read, "I believe 2023 is shaping up to be an exciting year for Principal with a number of major milestones on the horizon, both for the Company and its Portfolio Investments. With strategic agility, market potential, and stakeholder value as its driving priorities, our leadership team has recently taken a close look at our existing partnerships, investments, and joint ventures in order to refine Principal's corporate focus and streamline its activities - and ultimately increase the likelihood of the Company's overall success and profitability. As a result, we are in the process of divesting Principal of business activities, investments, and relationships that we feel are not in line with our renewed and sharpened corporate focus. Fortunately, we're already seeing the benefits of this streamlining process in the quality and effectiveness of our new business relationships. Through our recently announced joint venture with Executive Logistics & Transportation, we've been able to focus our efforts on acquiring controlling working interest and assets in the Minerva-Rockdale Oil Field. A major potential win for Principal, this acquisition brings an immediate revenue stream realized from the current production of 200 barrels of oil per day* and huge upside potential with proven reserves of over 4.1 million barrels*, valued at approximately $116,000,000 in today's market. We plan to immediately begin working to increase daily production to 500 barrels within the first six months of executing our definitive agreement. The Minerva-Rockdale Oil Field is huge - 11,000 gross acres - and in our view, ripe for expansion with mineral rights into two deeper areas with additional oil and natural gas reserves. On the other side of the energy spectrum, our ELT joint venture is bringing opportunities for eTruck Transportation in the logistics market. Principal is working closely with eTruck to deliver production-ready Class 6 heavy EV trucks for customer evaluation. Class 6 vehicles are mainstays in fleets, used primarily for city, urban, and local ranged deliveries. eTruck, one of Principal's Portfolio Investments, is developing a range of Class 6 and Class 8 heavy electric vehicle conversion solutions in both hybrid and fully electric configurations. eTruck recently released a video update showcasing its new facility as well as its vehicle conversion prototypes. On the business front, we've recently retained a PCOAB auditor and attorney for a possible future S-1 filing, and we're negotiating with an existing PSWW investor for an S-1 equity line in order to provide near-term funding. We've also recently engaged Institutional Advisors, Inc. to provide analyst coverage of PSWW, thereby helping to ensure our current and future investors are up to speed on our progress and fully aware of our market opportunities and value potential. Be sure to visit Principal's newsroom for all of our latest announcements. With today's strong petroleum markets and the significant and growing customer and consumer demand for cost-effective, heavy electric vehicles, I'm bullish on our prospects for 2023, as I feel we're ideally positioned to deliver maximum stakeholder value on both fronts. I'm glad to have you as a fellow stockholder and look forward to delivering further updates in the coming months."

07:47 EDT Nextech3D.ai reports Toggle3D crosses over 1000 sign-ups - Nextech3D.AI announced its AI-powered SaaS CAD to 3D Design Platform, Toggle3D.ai has crossed over 1000 sign-ups on the platform. Toggle3D.ai enables the conversion, texturing, customizing and sharing of the highest quality 3D models at scale, using CAD files. Since the Beta launch, the platform has attracted a variety of users such as designers, developers, 3D artists, entrepreneurs and creators, reaching over 1000 users on the platform within 2 months which is a +963% change since the start of the year.

07:43 EDT Accenture says initiated actions to streamline operations in Q2 - During the second quarter of fiscal 2023, Accenture initiated actions to streamline operations, transform non-billable corporate functions and consolidate office space to reduce costs. The company recorded $244M in business optimization costs during the second quarter and expects to record total costs of approximately $1.5B through fiscal 2024. Accenture estimates $1.2B for severance and $300M for consolidation of office space, with approximately $800M expected in fiscal 2023 and $700M in fiscal 2024.

07:41 EDT PLBY Group directors buy $9.4M, and $18.7M in common stock - In regulatory filings, PLBY Group disclosed that its director John Giampetroni bought 3.7M shares for $9.4M and its director Suhail Rizvi bought 7.3M shares for $18.7M on March 21st. Shares of PLBY Group are up 3.6% at $2.02 in pre-market trading.

07:35 EDT BridgeBio announces first patient dosed in Phase 1 trial of BBP-398 with OPDIVO - BridgeBio Pharma (BBIO) announced that the first patient with non-small cell lung cancer, NSCLC, has been dosed in its Phase 1/2 clinical trial of BBP-398, an investigational SHP2 inhibitor, with Bristol Myers Squibb's (BMY) OPDIVO in advanced solid tumors with KRAS mutations. "SHP2 has been shown to be a key regulator of both tumor and immune cell signaling. In KRAS mutant tumors, SHP2 promotes survival, proliferation and decreased immunogenicity by driving the active form of KRAS, while in immune cells, it associates with PD-1 which leads to immunosuppression in the tumor microenvironment," said Eli Wallace, Ph.D., chief scientific officer of oncology at BridgeBio. "By partnering with Bristol Myers Squibb on this trial, we hope to show that targeting PD-1 with a two-prong approach can unlock the potent benefits of immunotherapy against this cancer and provide new treatment options for patients who need them."

07:32 EDT Monte Rosa Therapeutics appoints Jan Skvarka to board of directors - Monte Rosa Therapeutics announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors. Dr. Skvarka currently serves as the Executive Chairman of DEM BioPharma, Inc., and as a Board Member of Zentalis Pharmaceuticals.

07:26 EDT Parsons secures $14M task order contract from DOE OCED - Parsons Corporation announced that the company was selected by the U.S. Department of Energy Office of Clean Energy Demonstrations to accelerate clean energy technologies from the lab to market. The new $14M ceiling-value task order contract includes a one-year base period with two option period years and was awarded under the National Nuclear Security Administration Enterprise Construction Management Services contract that the company was awarded in June 2022.

07:23 EDT Moderna, Generation Bio enter collaboration for non-viral genetic medicines - Moderna (MRNA) and Generation Bio (GBIO) announced that the two companies have entered into a strategic collaboration to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform. The collaboration aims to expand the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines. Under the terms of the agreement, Moderna may advance two immune cell programs, each of which may use a jointly developed ctLNP to deliver ceDNA. In addition, Moderna may advance two liver programs, each of which may use a liver-targeted ctLNP developed by Generation Bio to deliver ceDNA. Moderna retains an option to license a third program for either immune cells or the liver. Generation Bio will receive a $40M upfront cash payment and a $36M equity investment issued at a premium over recent share prices. Moderna will fund all collaboration work, including a research pre-payment. Generation Bio is also eligible for future development, regulatory and commercial milestone payments, as well as royalties on global net sales of liver-targeted and immune cell-targeted products commercialized under the agreement. The agreement additionally provides Moderna with the right, subject to certain terms and conditions, to purchase additional shares of common stock in connection with a future equity financing by Generation Bio. Further, Moderna and Generation Bio will both leverage collaboration research to continue to advance in vivo immune cell targeting as a new class of genetic medicines, with downstream economics on products utilizing such technology. Generation Bio is eligible to receive certain exclusivity fees as well as potential development and regulatory milestones and royalties on products that Moderna advances using ctLNP technology developed under the collaboration.

07:20 EDT UAL and Archer announce 1st commercial electric air taxi route in Chicago - Archer Aviation (ACHR) and United Airlines (UAL) announced plans to launch the first air taxi route in Chicago, between O'Hare International Airport ORD and Vertiport Chicago. Vertiport Chicago, North America's largest vertical aircraft takeoff and landing facility, is located in the Illinois Medical District near the Chicago Loop. This site was selected as the takeoff and landing site for this airport to city center route because of its unparalleled convenience, access and service. From there, passengers will be able to travel to and from ORD via Archer's Midnight aircraft in approximately 10 minutes. A similar trip by car can take upwards of an hour or more during rush hour traffic. United Airlines and Archer have selected O'Hare International Airport to Vertiport Chicago as the next point to point route in which the two companies will utilize Archer's electric vertical takeoff and landing eVTOL aircraft. United and Archer's goal for its UAM network is to provide residents and visitors in the Chicago Metropolitan Area with a safe, sustainable, low noise, and cost-competitive alternative to ground transportation beginning in 2025. Chicago is the third most populous city in the United States, a center for business, innovation and investment, and home to United's headquarters. This makes it a unique city for Archer and United to build out. The early launch routes will focus in on airport to city center transportation service, which are referred to as "trunk" routes. Once the trunk routes have been established, the next step will be to build out "branch" routes to connect to surrounding communities. "Both Archer and United are committed to decarbonizing air travel and leveraging innovative technologies to deliver on the promise of the electrification of the aviation industry," said Michael Leskinen, President of United Airlines Ventures. "Once operational, we're excited to offer our customers a more sustainable, convenient and cost-effective mode of transportation during their commutes to the airport."

07:14 EDT Bombardier targets over $9B in annual revenue by 2025 - Bombardier will host its 2023 Investor Day this morning. Eric Martel, Bombardier's President and CEO, along with Paul Sislian, Executive Vice President, Aftermarket Services & Strategy, and Bart Demosky, Executive Vice President and Chief Financial Officer, will present an overview of the company's solid progress made and new opportunities for diversified growth. "In 2021, we laid the foundation for a stronger, more resilient and predictable Bombardier by 2025. Halfway down the road, we can say we are delivering on that promise," said Martel. "All of Bombardier's strategic priorities are on track or ahead of plan. We are therefore proud to announce today that we are confidently raising the bar. The future is bright for Bombardier. While we are carefully monitoring the current market situation, we know that we have all the ingredients in place to remain a driving force in the industry. Our financial performance allows us to secure our vision for the future, and enable our exceptional, dedicated and passionate teams to lead the way toward more sustainable aviation." Based on strong business execution and fundamentals, Bombardier will announce that it is updating its 2025 objectives. The company is now targeting more than $9 billion in annual revenue by 2025, with an adjusted EBITDA of more than $1,625 million, and a healthy adjusted EBITDA margin of approximately 18%. Bombardier also expects to generate significant free cash flow in the coming years, to the tune of more than $900 million per year by 2025 and will continue to de-lever its business, now expecting to reach a net leverage ratio in the range of 2.0x to 2.5x.

07:12 EDT Euronet's Ria Money Transfer to sponsor FC Internazionale Milano - Ria Money Transfer, a business segment of Euronet, announced an agreement to become an official sponsor of the Italian football club FC Internazionale Milano through the 2025 season. This new sports sponsorship will help raise awareness of Ria's brand in Italy and benefit Euronet's Money Transfer segment, which includes Ria Money Transfer, Xe and Dandelion globally. "We are proud to be an official sponsor of such a historic and successful football club. This new sponsorship makes perfect sense, given the similarities between Inter's history and our own," said Juan Bianchi, CEO of Euronet's Money Transfer segment.

07:10 EDT Aldebaran Resources appoints Adam Greening to SVP, corporate development - Aldebaran Resources announced the promotion of two of its employees. Javier Roberto has been promoted from Country Manager, Argentina to Vice President and Country Manager, Argentina. Javier has worked with Aldebaran since its inception in 2019 and prior to working with Aldebaran, he worked with Regulus Resources and Antares Minerals, both companies run by senior management of the Company. Javier has been a major contributor in advancing the Company's business plan within Argentina and will continue to do so in his expanded role. Adam Greening has been promoted from Vice President, Corporate Development to Senior Vice President, Corporate Development. Adam has worked with Aldebaran since March 2019 and has played a key role in developing and advancing business strategy within the Company.

07:09 EDT Arch Biopartners receives funding for development of LSALT peptide program - Arch Biopartners is receiving advisory services and up to $4,000,000 in funding from the National Research Council of Canada Industrial Research Assistance Program to support the research and development of the LSALT peptide program. LSALT peptide is the Company's lead drug candidate for treating acute inflammation injury in the lungs, kidneys and liver. The research and development funding from NRC IRAP will help support several sub-tasks needed to advance the LSALT peptide drug program. These include: dose escalation studies; costs incurred by Arch during the Canadian Treatments for COVID-19 Phase III human trial; manufacturing new drug product supply to support future non-COVID human trials; the non-COVID Phase II trials to gather more human data to support future drug approval; and, additional non-clinical studies to discover potential biomarkers and to further understand the mechanism of action related to LSALT peptide. The term of the Project extends to March 31, 2024.

07:07 EDT Ford backs FY23 adjusted EBIT view $9B-$11B - The company said, "Additionally, Ford will: Reiterate a 10% margin target for company adjusted EBIT (earnings before interest and taxes) by the end of 2026; Confirm that, among the new business segments, Ford Blue and Ford Pro are both solidly profitable and well-positioned for growth; Repeat its 8% EBIT margin objective by late 2026 for Ford Model e, which is tied to planned global electric vehicle production run rates of 600,000 units by the end of 2023 and two million by the end of 2026; Say that the contribution margin of Ford Model e's first-generation EVs - representing revenue minus certain variable costs - is expected to approach break-even this year, but be more than offset on an EBIT basis by higher investments in new EV products and manufacturing capacity; Reiterate that it anticipates full-year adjusted EBIT to be $9B to $11B - and adjusted free cash flow to be about $6B- based on assumptions outlined in the fourth-quarter 2022 earnings release on Feb. 2, and provide 2023 segment-level EBIT expectations: about $7B for Ford Blue, a modest improvement from last year; a full-year loss of about $3B for Ford Model e; and EBIT approaching $6B for Ford Pro, nearly twice its 2022 earnings."

07:07 EDT Generation Bio, Moderna announce strategic collaboration - Moderna (MRNA) and Generation Bio (GBIO) announced that the two companies have entered into a strategic collaboration to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform. The collaboration aims to expand the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines. Under the terms of the agreement, Moderna may advance two immune cell programs, each of which may use a jointly developed ctLNP to deliver ceDNA. In addition, Moderna may advance two liver programs, each of which may use a liver-targeted ctLNP developed by Generation Bio to deliver ceDNA. Moderna retains an option to license a third program for either immune cells or the liver. Generation Bio will receive a $40 million upfront cash payment and a $36 million equity investment issued at a premium over recent share prices. Moderna will fund all collaboration work, including a research pre-payment. Generation Bio is also eligible for future development, regulatory and commercial milestone payments, as well as royalties on global net sales of liver-targeted and immune cell-targeted products commercialized under the agreement. Further, Moderna and Generation Bio will both leverage collaboration research to continue to advance in vivo immune cell targeting as a new class of genetic medicines, with downstream economics on products utilizing such technology.

07:05 EDT Darden reports Q3 blended same-restaurant sales increase of 11.7% - Q3 same-restaurant sales by segment: Olive Garden 12.3 %; LongHorn Steakhouse 10.8 %; Fine Dining 11.7%; Other Business 11.7%.

07:04 EDT Ford to report financial results based on three new global business segments - Ford will walk investors, analysts and others through how the company is now organized and operating - and will report financial results - based on three new global business segments that are focused on different automotive customers, rather than by geographic regions. The "teach-in" event will be held at 10:00 a.m. Eastern Time at the New York Stock Exchange and streamed, "live" and on replay, via shareholder.ford.com. Ford said Controller Cathy O'Callaghan will highlight how three principles guided the new segmentation: Fairly representing the business models of each segment; Giving the Ford Blue, Ford Model e and Ford Pro teams both the latitude and accountability for their success, and being easy to understand and simple to execute, so that everyone can see how Ford is generating value for customers and other stakeholders.

06:53 EDT Accenture reports Q2 new bookings $22.1B - New bookings for the quarter were a record $22.1B, with consulting bookings of $10.7B and managed services bookings of $11.4B.

06:50 EDT AstraZeneca says Calquence conditionally approved in China for first indication - AstraZeneca's Calquence, a next generation, selective Bruton's tyrosine kinase inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma, or MCL, who have received at least one prior therapy, the company announced. "This is the first approved indication for Calquence in China," AstraZeneca stated.

06:48 EDT Accenture raises FY23 operating cash flow view to $8.7B-$9.2B - For fiscal 2023, the company now expects operating cash flow to be in the range of $8.7 billion to $9.2 billion compared to $8.5 billion to $9.0 billion previously; property and equipment additions to be $700 million, compared to $800 million previously; and free cash flow to be in the range of $8.0 billion to $8.5 billion, compared to $7.7 billion and $8.2 billion previously. The company continues to expect to return at least $7.1 billion in cash to shareholders through dividends and share repurchases.

06:37 EDT KBR acquires Acetica, terms undisclosed - KBR announced that it has acquired Acetica, an acetic acid production technology, which expands KBR's petrochemicals value chain through a profitable pathway for CO2 utilization.

06:34 EDT Gilead, Pionyr Immunotherapeutics change 2020 exclusive option agreements - Pionyr Immunotherapeutics announced that Pionyr and Gilead Sciences have mutually agreed to change their 2020 exclusive option agreements. Gilead has waived its exclusive option to acquire Pionyr and certain other rights under the 2020 agreements. Gilead will retain its 49% equity stake in Pionyr as well as its right, under certain conditions, to review new data as it emerges. Pionyr is now free to pursue fundraising and partnering opportunities as part of its ongoing strategy. Pionyr is continuing Phase 1b development of two monoclonal antibody drugs targeting TREM1 and TREM2 and is poised to file an IND this year for a third program targeting MARCO. TREM2, TREM1 and MARCO represent novel targets present on distinct populations of myeloid cells in the tumor microenvironment associated with suppression of the immune response to multiple tumor types. In Phase 1a and 1b studies, PY314 and PY159 have demonstrated encouraging safety and tolerability both alone and in combination with pembrolizumab warranting further clinical investigation. PY314, PY159 and PY265 are first-in-class assets that target these cellular populations to enhance anti-tumor immunity. In 2020, Gilead paid $275M for its equity stake in Pionyr and agreed to fund Pionyr's clinical and research activities in exchange for an exclusive option to acquire Pionyr for a pre-set price and contingent payments. As part of this agreement, Gilead waives its exclusive option to acquire Pionyr. Pionyr will be responsible for ongoing development of its pipeline, which includes PY159, PY314 and PY265. The company has the resources to advance its pipeline for the next two years. Within that timeframe, Pionyr will continue enrollment in Phase 1b expansion cohorts for both PY159 and PY314 in the refractory setting and is planning to add new frontline cohorts for both candidates. Pionyr has also completed IND-enabling studies for PY265 and will be ready to file an IND for that program in 2023.

05:16 EDT Regeneron, Sanofi report Dupixent trial meets primary and secondary endpoints - Regeneron (REGN) and Sanofi (SNY) announced the primary and all key secondary endpoints were met in a Phase 3 trial evaluating the investigational use of Dupixent compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease, or COPD, and evidence of type 2 inflammation. Dupixent is the first and only biologic to demonstrate a clinically meaningful and highly significant reduction in moderate or severe acute exacerbations of COPD over 52 weeks, while also demonstrating significant improvements in lung function, quality of life and COPD respiratory symptoms. In the BOREAS trial, 939 adults who were current or former smokers aged 40 to 80 years were randomized to receive Dupixent or placebo added to maximal standard-of-care inhaled therapy. Patients receiving Dupixent experienced: 30% reduction in moderate or severe acute COPD exacerbations over 52 weeks, the primary endpoint. Improved lung function from baseline by 160 mL at 12 weeks compared to 77 mL for placebo, with the benefit versus placebo sustained through week 52, both of which were key secondary endpoints. Dupixent met all endpoints tested in the hierarchy, including improvement in patient-reported health-related quality of life as measured by the St. George's Respiratory Questionnaire and reduction in the severity of respiratory symptoms of COPD as measured by Evaluation Respiratory Symptoms: COPD Scale. The safety results were generally consistent with the known safety profile of Dupixent in its approved indications. Overall rates of adverse events were 77% for Dupixent and 76% for placebo. AEs more commonly observed with Dupixent compared to placebo included headache, diarrhea and back pain. AEs more commonly observed with placebo compared to Dupixent included upper respiratory tract infection, hypertension and COVID-19. AEs leading to deaths were balanced between the two arms. Detailed efficacy and safety results from this trial will be presented in a future scientific forum. The broader Sanofi and Regeneron COPD clinical research program includes Phase 3 trials with itepekimab, a fully human monoclonal antibody that binds to and inhibits interleukin-33, or IL-33. Itepekimab received Fast Track Designation from the FDA in January 2023 for the treatment of COPD in patients who do not currently smoke. Data from this program is expected in 2025. The safety and efficacy of Dupixent and itepekimab in COPD have not been fully evaluated by any regulatory authority.

05:06 EDT PureTech Health sells interest in KarXT to Royalty Pharma for up to $500M - PureTech Health (PRTC) and Royalty Pharma (RPRX) announced that Royalty Pharma has acquired an interest in PureTech's royalty in Karuna Therapeutics' KarXT for up to $500M, with $100M in cash up front and up to $400M in additional payments contingent on the achievement of certain regulatory and commercial milestones. As part of this transaction, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on sales up to $2 billion annually, after which threshold Royalty Pharma will receive 33% and PureTech will retain 67% of the royalty payments. PureTech retains its 3.1% equity ownership in Karuna.1 Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals and 20% of sublicense income.